Ammonia in Disguise
A tumor has a nitrogen problem. One transamination solves it — and the molecule that does the solving also carries carbon out and a standing order for glucose back.
Measure ammonia in a tumor and you will find some. Measure the nitrogen actually leaving that tumor and you will find considerably more than the ammonia accounts for.
The difference is travelling under another name.
Part I / The Nitrogen Problem
The Reaction Nobody Looks at Twice
Alanine aminotransferase does something almost embarrassingly simple. It takes pyruvate — the end product of glycolysis, the chain of reactions that breaks glucose apart, and a molecule every cell makes by the bucketful — and swaps an oxygen atom for an amino group, a nitrogen with its hydrogens, borrowed from the amino acid glutamate.
That is the whole reaction. Two versions of the enzyme run it — one in the body of the cell (ALT1/GPT) and one inside the mitochondria (ALT2/GPT2) — and it is fully reversible, meaning it can run in either direction. Which way it goes depends only on what is abundant on each side.
If you have ever had liver blood tests, you have already met this enzyme without being introduced. ALT is one of the numbers on the report, and it is there for a simple reason: when liver cells are damaged, their contents spill into the blood, and this is one of the things that spills.
It is not usually presented as a piece of cancer biology, and that is a shame — because in a tumor this enzyme is not spilling out of anything. It is running a logistics operation.
Ammonia: A Weapon the Tumor Can Also Die From
Start with the problem the operation exists to solve.
A fast-growing tumor burns through amino acids. It consumes glutamine at rates second only to glucose, and many tumors also break down the branched-chain amino acids — leucine, isoleucine and valine, the ones most abundant in muscle protein. Every amino acid broken down liberates a nitrogen atom that the cell now has to do something with. The naive solution is to release it as ammonia.
And here is where it gets interesting, because ammonia in a tumor is not simply waste. It is a weapon. A broad metabolic survey of a mouse model of metastatic colorectal cancer found a robust accumulation of ammonia inside the tumor, and those elevated levels pushed the local T cells into exhaustion — a worn-out state in which they stop multiplying and stop killing. Clearing the ammonia reactivated them, shrank the tumors, extended survival, and improved the response to anti-PD-L1, one of the checkpoint immunotherapies. A separate line of work describes glutamine-derived ammonia killing effector T cells outright — the ones that do the actual destroying of tumor cells — by a mechanism provisionally called "ammonia death," alongside evidence that ammonia favors regulatory T cells, whose job is to damp immune responses down.
So ammonia suppresses the immune system. A tumor benefits from that.
But ammonia is indiscriminate. It disrupts pH, mitochondria, and nitrogen metabolism in whatever cell it reaches, and the cell producing it is the one standing closest. A tumor that simply dumped all its surplus nitrogen as free ammonia would poison its own stroma, its own mitochondria, and eventually itself.
Transamination is the valve. Instead of cutting the nitrogen loose, the cell hands it to a carrier. Glutamate accepts nitrogen from other amino acids, alanine aminotransferase moves it onto pyruvate, and the nitrogen leaves as alanine — soluble, neutral, unremarkable, and invisible to the assay we use to look for nitrogen stress.
Pyruvate is what makes this possible. It is the acceptor. A cell with nitrogen to shed and no pyruvate available has a problem. A cell with pyruvate in surplus has a disposal route that costs it nothing and poisons nobody.
And a tumor that runs on glycolysis has pyruvate in surplus by definition. The Warburg effect — the tumor habit of burning glucose down to lactate even when there is plenty of oxygen available to do better — is usually told as a story about energy: inefficient fuel use, lactate as exhaust. Seen from the nitrogen side it reads differently. A cell running glycolysis hard is continuously manufacturing the exact molecule it needs in order to export nitrogen safely.
Part II / Three Services
What Alanine Actually Carries
Once the nitrogen is loaded onto pyruvate, the resulting molecule is doing three jobs at once. They are usually described in three separate literatures, by three separate communities, and almost never in the same paragraph.
Service one
Carbon, moved
Three carbons the tumor did not finish oxidizing, exported intact rather than wasted.
Service two
Nitrogen, shed silently
A nitrogen atom disposed of without ever appearing as free ammonia.
Service three
A bill sent to the liver
Carbon the liver will rebuild into glucose and return — at its own expense.
And in reverse
Carbon, delivered
In pancreatic tumors the stroma runs the reaction the other way and feeds the cancer.
Service One: The Stroma Delivers
The clearest demonstration of alanine-as-fuel came from pancreatic cancer. Those tumors sit inside a dense wall of fibrous tissue, and the cells that build that wall — pancreatic stellate cells — turn out to be feeding the cancer. They secrete alanine, which outcompetes carbon from both glucose and glutamine as a fuel for the tumor's mitochondria, and for the fats and amino acids it needs to grow.
The mechanism is the part that should make you sit up. The stellate cells are not passively leaking. They are digesting their own internal components in order to produce that alanine — a normal survival process called autophagy, by which a cell recycles its own parts under stress — and the cancer cells are the ones sending the signal that switches it on. Block autophagy in the stellate cells alone, and tumor growth in mice largely stops.
Note what this costs the tumor: nothing. In an environment where glucose and blood-borne nutrients are genuinely scarce, it has a parallel supply line that drugs aimed at glucose metabolism do not touch, paid for by somebody else's self-digestion.
Service Three: A Standing Order to the Liver
Alanine released into the blood goes to the liver, which does two things with it. It strips the nitrogen off and routes it into the urea cycle, and it takes the three carbons left over — now pyruvate again — and builds glucose. That glucose re-enters circulation, where a glucose-hungry tumor is waiting.
liver: alanine → NH3 → urea | alanine → pyruvate → glucose → back to tumor
This is the glucose–alanine cycle, described in healthy physiology decades ago as the way exercising muscle offloads nitrogen and recycles carbon. A tumor does not invent it. A tumor subscribes to it.
The clearest measurement comes from an unlikely model: adult zebrafish carrying BRAF-driven melanoma. Those tumors consumed roughly fifteen times more glucose than any other tissue measured, and yet the animals' circulating glucose stayed normal. The reason was a tumor–liver alanine cycle. The melanoma exported glucose-derived alanine, which gave the liver carbon for gluconeogenesis and simultaneously let the tumor dump excess nitrogen from branched-chain amino acid breakdown — a pathway the authors found switched on in human melanoma too. Block the cycle pharmacologically and tumor burden fell.
Notice who pays. Rebuilding glucose is expensive; the liver spends its own energy reconstructing a fuel the tumor declined to finish burning. The glucose–alanine cycle is less efficient than the Cori cycle, the equivalent loop that recycles lactate, so the host absorbs an even larger loss. Wasteful loops of exactly this kind, running between organs, are one of the standing explanations for cancer cachexia — the progressive wasting that accounts for a large share of cancer deaths and that nobody has been able to treat.
Part III / The Architecture
Where It Stops Looking Opportunistic
Take the three services together.
A single transamination lets a tumor move carbon it cannot finish oxidizing, shed nitrogen it cannot safely hold, and place a standing order with the liver for the fuel it most depends on. Three problems, three solutions, one molecule, one enzyme, one step. There is no elaborate machinery being assembled. Just pyruvate, which the tumor already has in surplus, and a transferase almost every cell carries.
That is the moment the picture changes. On its own, each service reads as a cell making do. Together they read as an architecture.
And the enzyme pays out in both directions. Remember that the reaction produces α-ketoglutarate alongside the alanine — a small molecule that an entire family of enzymes requires in order to function at all. Run the reaction one way and α-ketoglutarate accumulates, switching those enzymes on; among them are the ones that stiffen the collagen scaffolding around a growing metastasis. That is the mechanism by which breast cancer cells use pyruvate from their surroundings to build their foothold in the lung. Run it the other way and α-ketoglutarate falls, disabling the cell's oxygen sensor — which would otherwise destroy HIF-1α, the master switch for the low-oxygen survival program. A separate study found exactly this, with GPT2 overexpression stabilizing HIF-1α and expanding the pool of stem-like cancer cells.
Run it forward
pyruvate → alanine
α-KG rises. The collagen-stiffening enzymes switch on, and the scaffolding hardens around a forming metastasis.
Run it backward
alanine → pyruvate
α-KG falls. The oxygen sensor stalls, the low-oxygen switch stays on, and the pool of stem-like tumor cells expands.
Two papers, the same enzyme, opposite effects on the same molecule, both working in the tumor's favor. That is not a contradiction in the literature. It is mass action — the ordinary chemical rule that a reversible reaction runs away from whatever is piled up. Whichever ingredient is abundant sets the direction. The tumor wins either way.
The Asymmetry That Decides Who Benefits
All of which raises an obvious objection. Alanine is a common amino acid. The tumor microenvironment is not a private room. If alanine is floating around, why do the immune cells not simply use it too?
They would like to. In 2019 a group at Harvard and Princeton asked what a resting T cell needs in order to wake up and become a killer, and found something unexpected: T cells require alanine from outside themselves in order to activate. Deprive them of it and the whole process falters. Memory T cells — the ones held in reserve from a previous encounter — need it again to wake up a second time.
This is strange on its face. Alanine is one transamination away from pyruvate, and T cells have plenty of pyruvate. Why would they need to import it?
The answer is the whole point. T cells barely make alanine aminotransferase at all. They cannot run the reaction. What they do instead, on waking up, is switch on alanine transporters — pumps that pull it in from outside. And when you feed them labelled alanine and follow the atoms, they do not even burn it. They use it to build protein.
| Tumor cells | T cells | |
|---|---|---|
| Alanine aminotransferase | High; GPT2, the mitochondrial form, rises with tumor grade | Barely present |
| Can convert pyruvate → alanine | Yes, in either direction as conditions favor | No |
| Can import alanine | Yes | Yes, via transporters induced on activation |
| Role in the exchange | Sets the direction and the supply | Takes whatever is available |
That asymmetry is not a detail. The same molecule arrives as a strategic asset for one cell type and as a dependency for the other — and only one of them controls the tap. We already know which way the local default points: in pancreatic tumors the stroma is running an alanine delivery service, and it is aimed at the cancer.
So the immune cell in that space is competing for a nutrient it cannot make, against a cell that can make it, in an environment that cell has already organized. And it is doing so while the free ammonia the tumor did release is independently pushing it toward exhaustion.
Part IV / Consequences
What This Means for Measurement
If most of a tumor's surplus nitrogen leaves as alanine rather than ammonia, then ammonia concentration is a poor proxy for nitrogen flux. The two can move independently — and a tumor that is good at transamination can run an enormous nitrogen turnover while keeping free ammonia at a level that looks almost unremarkable.
That is worth stating plainly, because it cuts against an intuition the field has been building on. A low or moderate tumor ammonia reading does not mean the nitrogen economy is quiet. It may mean the opposite: that the valve is working.
A Warning About Lactate Oxidase
There is a class of therapy where this matters immediately.
Tumor lactate suppresses immune function, so a reasonable idea is to destroy it — and several groups are now delivering a bacterial enzyme called lactate oxidase into tumors, wrapped in nanocapsules, carried by engineered gut bacteria, or packaged into the tiny vesicles those bacteria shed. The published results are encouraging: lactate falls, T cells move in, checkpoint immunotherapy works better.
But look at what the enzyme actually does. Lactate oxidase converts lactate into pyruvate. Which is to say: a therapy designed to disarm the tumor's immunosuppression manufactures, inside the tumor, the exact substrate the transaminase needs — the acceptor for nitrogen disposal, the carbon for the liver loop, the input to the α-ketoglutarate switch.
→ alanine + α-KG | → back to lactate | → acetyl-CoA | → acetate
Nobody has tested this. The pyruvate left behind is almost never measured in these studies; alanine, as far as I can find, never. And the pro-tumor effects of surrounding pyruvate that have been demonstrated are mostly about preparing the ground where metastases take root, rather than about the growth of the original tumor — so experiments designed as these are, reporting the size of the primary tumor, would not detect the problem even if it were happening.
That is a cheap thing to check. Measure the alanine. Follow the animals for metastases, not just tumor size. Run the enzyme alongside a drug that blocks transamination, and see whether stopping the conversion makes the therapy work better or worse.
The Orchestrator That Never Shows Its Face
I am not concluding ammonia is secretly in charge (although it may be). But nitrogen flux and ammonia concentration are different variables, and we have been measuring, if at all, the second while reasoning about the first.
If that is right, the consequence is not a footnote. Every estimate of how much ammonia matters in cancer has been made with an instrument that cannot see most of the traffic — one that reads a well-run nitrogen economy as a quiet one. We do not know how large ammonia's role is. We know that the way we have been looking could only ever have made it look small.
A tumor that handles nitrogen well keeps the free ammonia in a band: high enough to exhaust T cells, low enough not to damage itself. Everything above that band goes out bound to pyruvate, as an amino acid so ordinary it does not register as a finding. The nitrogen does its work and leaves without a signature.
Which raises the question worth ending on. We have a long habit of sorting tumor metabolites into fuels and wastes, and alanine has always sat in the second pile — a nitrogen carrier, a liver enzyme's substrate, a line in a textbook. How many other molecules have we filed under waste that are, on inspection, doing three jobs at once?
%20(3).png)
No comments:
Post a Comment